HopeStage
Back to all studies
CompletedNCT03720847

Ovarian Hormone Supplementation and Suicidal Symptoms Around the Menstrual Cycle

About this title

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

Read the official source — NCT03720847
Medication studyAges 18–45United StatesSuicide prevention
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 45 years.

Listed locations
Chapel HillSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 31, 2016
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
University of North Carolina, Chapel Hill
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT03720847
Official title
Show the full official title

Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Chapel Hill

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of North Carolina, Chapel Hill, a university.

Did this study involve medication?

Yes. The study involved medication, including Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch and Placebo capsule.

Who was this study for?

Listed age limits: 18 years to 45 years.

Want to explore more studies?

Explore studies